Drug Discovery

Allergan to buy clinical-stage biotechnology firm Bonti for $195m

Irish drug maker Allergan has agreed to acquire US-based clinical-stage biotech company Bonti in a deal worth more than $195m.

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

Boehringer Ingelheim has purchased all shares of Austrian biopharmaceutical firm, ViraTherapeutics, in a deal valued at around €210m.

Immunotherapy firm OncoResponse secures $40m series B financing

OncoResponse, an immunotherapy company developing a portfolio of novel antibodies for cancer, has announced the completion of a $40m series B equity financing.

Summit discovers new mechanism antibiotics to combat ESKAPE pathogen targets

Summit Therapeutics, a UK-based clinical-stage drug discovery and development company, claims to have discovered multiple new mechanism antibiotics against novel ESKAPE pathogen targets.

Fulcrum raises $80m funding to advance rare disease-focused pipeline

Fulcrum Therapeutics, a company engaged in discovery and development of small molecule therapies for the treatment of serious genetic diseases, has raised $80m in a Series B funding round.

Aurobindo to buy parts of Sandoz US from Novartis for $900m

Aurobindo Pharma USA has agreed to acquire selected portions of Sandoz US portfolio from Novartis for $900m of cash and $100m of potential earn-outs.

Boehringer, Tsinghua University to develop immunological therapies for infectious diseases

German pharma company Boehringer Ingelheim has announced a collaboration with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases.

Evotec, CHDI Foundation expand collaboration for Huntington’s disease

CHDI Foundation has extended its collaboration with Evotec through to 2023 to fight against Huntington's disease, a familial disease caused by a mutation in the huntingtin gene.

Data science company IXICO extends contract with biopharmaceutical firm

IXICO, the data science company offering insights in neuroscience, has signed a further change order to a current contract which increases the total contract value to €1.3m.